Phases in drug developments i pre clinical studies
This presentation is the property of its rightful owner.
Sponsored Links
1 / 31

Phases in drug developments I: Pre-clinical studies PowerPoint PPT Presentation


  • 41 Views
  • Uploaded on
  • Presentation posted in: General

Phases in drug developments I: Pre-clinical studies. Kausar Ahmad Department of Pharmaceutical Technology Kulliyyah of Pharmacy [email protected] http://staff.iium.edu.my/akausar. Phases in drug development. Preformulation. Physicochemical properties. Physicochemical properties.

Download Presentation

Phases in drug developments I: Pre-clinical studies

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Phases in drug developments i pre clinical studies

Phases in drug developments I: Pre-clinical studies

Kausar Ahmad

Department of Pharmaceutical Technology

Kulliyyah of Pharmacy

[email protected]

http://staff.iium.edu.my/akausar

RM-KAHS


Phases in drug development

Phases in drug development

RM-KAHS


Preformulation

Preformulation

RM-KAHS


Physicochemical properties

Physicochemical properties

RM-KAHS


Physicochemical properties1

Physicochemical properties

RM-KAHS


Spectroscopy

Spectroscopy

RM-KAHS


Phases in drug developments i pre clinical studies

pKa

  • Determination of the dissociation constant for a drug - capable of ionization within a pH range of 1 to 10

  • This is important since solubility, and consequently absorption, can be altered by changing pH (buffer).

RM-KAHS


Rate of dissolution

Rate of dissolution

  • Determination of the rate is important when it is the rate limiting step in the drug absorption process.

  • If solubility of drug > 10 mg/ml, at pH7, there will be no problem of bioavailability or dissolution (Kaplan,1972)

RM-KAHS


Partition coefficient

Partition coefficient

RM-KAHS


Melting point

Melting Point

  • Affected by purity

  • Affected by types of polymorphs

RM-KAHS


Crystal properties polymorphism

Crystal Properties & Polymorphism

RM-KAHS


Particle properties

Particle properties

RM-KAHS


Powder flow compression properties

Powder Flow & Compression Properties

RM-KAHS


Phases in drug developments i pre clinical studies

Polyamide: Carrier for insoluble ingredients; Protector for sensitive ingredients; Slow delivery & long lasting effect

7 m, empty spheres

10 m, porous

PHM4153 Dosage Design 2 2011/12


Excipient particle size distribution

Excipient: Particle size distribution

PHM4153 Dosage Design 2 2011/12


Excipient pore volume pore diameter

Excipient: Pore volume & pore diameter

PHM4153 Dosage Design 2 2011/12


Chemical stability of active compounds

Chemical Stability of Active Compounds

RM-KAHS


Excipients product stability

Excipients & Product Stability

  • Excipients are important for processing and efficacy

    • For tablets: binders, disintegrants, lubricants, and fillers.

    • For liquids: preservatives, thickener, colorants, flavours, sweeteners, buffer and water

  • Techniques to screen drug-excipient compatibility:

    • Thin-layer chromatography

    • Differential thermal analysis

    • Diffuse reflectance spectroscopy

RM-KAHS


Incompatibility

Incompatibility

PHM4153 Dosage Design 2 2011/12


Detection of incompatibility

Detection of Incompatibility

PHM4153 Dosage Design 2 2011/12


Other factors to be considered in preformulation

Other factors to be considered in preformulation

RM-KAHS


Dosage form design

Dosage form design

RM-KAHS


Dosage form

Dosage form

RM-KAHS


Formulation

Formulation

PHM4153 Dosage Design 2 2011/12


Formulation requirement efficacy safety and quality

Formulation requirement: efficacy, safety, and quality

PHM4153 Dosage Design 2 2011/12


Categories of excipients

Categories of excipients

PHM4153 Dosage Design 2 2011/12


Choosing excipients

Choosing excipients

PHM4153 Dosage Design 2 2011/12


Pharmaceutical evaluation

Pharmaceutical evaluation

RM-KAHS


Example

Example

RM-KAHS


Summary

Summary

RM-KAHS


References

References

Aulton, M.E. (2002). Pharmaceutics – The Science of Dosage Form Design (2nd Ed.). Churchill Livingstone.

Bugay, D. E. (1999). Pharmaceutical excipients : characterization by IR, Raman, and NMR spectroscopy.

Kibbe, A. H. (2000). Handbook of pharmaceutical excipients.

Rowe, R. C., Sheskey, P. J. & Owen, S. C. (2006). Handbook of pharmaceutical excipients

Rowe, R. C. (2009). Handbook of pharmaceutical excipients.

RM-KAHS


  • Login